420132
JAK2 Inhibitor II
The JAK2 Inhibitor II, also referenced under CAS 1837-91-8, controls the biological activity of JAK2. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
别名:
JAK2 Inhibitor II, 1,2,3,4,5,6-Hexabromocyclohexane
登录查看公司和协议定价
所有图片(1)
About This Item
推荐产品
品質等級
化驗
≥97% (GC)
形狀
solid
製造商／商標名
Calbiochem®
儲存條件
OK to freeze
protect from light
顏色
off-white
溶解度
DMSO: 5 mg/mL
運輸包裝
ambient
儲存溫度
2-8°C
InChI
1S/C6H6Br6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-6H
InChI 密鑰
QFQZKISCBJKVHI-UHFFFAOYSA-N
一般說明
A cell-permeable hexabromocyclohexane compound that interacts with a solvent-accessible pocket near the activation loop of JAK2 and acts as a specific, reversible, and direct inhibitor of JAK2 autophosphorylation (maximal inhibition at 50 µM in BSC-40 cells overexpressing JAK2). Reduces growth hormone-mediated JAK2 activation in γ2A cells that stably express growth hormone receptor and JAK2. Does not block EGFR autophosphorylation in murine fibroblasts.
A cell-permeable, specific, reversible, and direct inhibitor of JAK2 autophosphorylation (maximal inhibition at 50 µM in BSC-40 cells overexpressing JAK2 that interacts with a solvent-accessible pocket near the activation loop of JAK2. Reduces growth hormone-mediated JAK2 activation in γ2A cells that stably express growth hormone receptor and JAK2. Does not block EGFR autophosphorylation in murine fibroblasts.
生化／生理作用
Cell permeable: yes
Primary Target
JAK2 autophosphorylation
JAK2 autophosphorylation
Product does not compete with ATP.
Reversible: yes
包裝
Packaged under inert gas
警告
Toxicity: Standard Handling (A)
重構
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
其他說明
Sandberg, E.M., et al. 2005. J. Med. Chem.48, 2526.
法律資訊
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral - Eye Irrit. 2
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Gerlinde Wernig et al.
Proceedings of the National Academy of Sciences of the United States of America, 114(18), 4757-4762 (2017-04-21)
Fibrotic diseases are not well-understood. They represent a number of different diseases that are characterized by the development of severe organ fibrosis without any obvious cause, such as the devastating diseases idiopathic pulmonary fibrosis (IPF) and scleroderma. These diseases have
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门